{"id":"W4379281186","doi":"10.1200/jco.2023.41.16_suppl.tps8070","title":"A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Carfilzomib; Internal medicine; Dexamethasone; Lenalidomide; Clinical endpoint; Multiple myeloma; Oncology; Cmax; Pharmacokinetics; Pharmacology; Urology; Gastroenterology; Surgery; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002699363,0.002360118,0.002890201,0.0004940847,0.0005189577,0.001382631,0.00127502,0.00181135,0.007754638],"category_scores_gemma":[0.00172651,0.0009012574,0.001960443,0.0004785463,0.001369624,0.001517362,0.0005561117,0.003913329,0.001479585],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001227769,"about_ca_system_score_gemma":0.002041644,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001260011,"about_ca_topic_score_gemma":0.003470334,"domain_scores_codex":[0.999342,0.0003398366,0.00002513724,0.0001137188,0.00005804944,0.0001212355],"domain_scores_gemma":[0.9987481,0.0002529604,0.0002731551,0.000118234,0.00006652054,0.0005410563],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9713722,0.01489416,0.0006479906,0.00019544,0.0004168226,0.00003579972,0.00004463598,0.0003838218,0.003090651,0.00009517966,0.0008403759,0.007982862],"study_design_scores_gemma":[0.8922558,0.1044701,0.001533413,0.00001380725,0.0001888657,0.00004076489,0.00002125207,0.0003940886,0.0002791905,0.0001785252,0.0006099874,0.00001424728],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843322,0.001970671,0.0008005131,0.0008357802,0.0004479599,0.007587973,0.002007303,0.0001575426,0.001859929],"genre_scores_gemma":[0.9728914,0.001929296,0.00294003,0.00225523,0.0005701709,0.01145483,0.003044971,0.00006484587,0.004849312],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007754638,"threshold_uncertainty_score":0.02594179,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1966314327749883,"score_gpt":0.5185551004945744,"score_spread":0.3219236677195861,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}